치료 역사
백혈병 치료 발전 타임라인
발견과 승인은 치료 선택의 역사를 보여줍니다. 하지만 개인에게 맞는 치료, 자격, 순서를 결정하지 않습니다.
오래된 치료가 항상 나쁜 것도 아니고, 최신 치료가 항상 맞는 것도 아닙니다. 진단명, 병기/단계, 유전자 검사, 이전 치료, 국가별 접근성에 따라 질문이 달라집니다.
한눈에 보기
치료 언어가 어떻게 바뀌었나
아래 도식은 순서나 우선순위가 아니라 큰 흐름입니다.
고위험 상황의 완치 의도 경로
BCR-ABL을 장기 조절의 언어로 바꿈
일부에서 치료 중단 연구가 가능해짐
선택된 ALL 상황에서 CAR-T 등장
새로운 기술이 생겼다고 해서 모든 환자에게 맞는 것은 아닙니다. 진단명, 단계, 검사 결과, 이전 치료, 국가별 접근성이 먼저입니다.
- transplant
1950s-1970s: Bone marrow and stem cell transplant becomes a curative-intent leukemia strategy
Doctors learned to rebuild blood-forming cells after intensive treatment using donor or patient stem cells.
무엇이 바뀌었나
For some leukemias, transplant created a possible curative-intent path, especially when relapse risk is high.
추정하면 안 되는 것
Transplant is not automatically better than medicine. It carries major risks and depends on subtype, phase, response, donor, age, health, and center experience.
의학적 세부 내용의 출처
- Stem Cell and Bone Marrow Transplants for Cancer. 확인일 2026-05-21.
- differentiation therapy
1988-2000s: APL shifts with differentiation therapy and arsenic trioxide
Acute promyelocytic leukemia became a model for treating a leukemia by pushing abnormal cells to mature rather than only killing dividing cells.
무엇이 바뀌었나
ATRA and arsenic trioxide transformed APL from one of the most dangerous acute leukemias into a highly treatable subtype when recognized and managed urgently.
추정하면 안 되는 것
APL is a special AML subtype. Its treatment logic should not be generalized to all AML, ALL, CLL, or CML.
의학적 세부 내용의 출처
- NCI: Arsenic Trioxide. 확인일 2026-05-21.
- Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version. 확인일 2026-05-21.
- targeted therapy
2001: Imatinib / Gleevec changes CML
A pill targeting BCR-ABL became a defining treatment for chronic myeloid leukemia.
무엇이 바뀌었나
CML became a flagship example of long-term cancer control with a targeted medicine for many patients.
추정하면 안 되는 것
Stable CML on TKI is not the same as being automatically cured, and medicine should not be stopped without the leukemia team.
의학적 세부 내용의 출처
- FDA: Information on Gleevec (Imatinib Mesylate). 확인일 2026-05-21.
- Chronic Myeloid Leukemia Treatment (PDQ) - Patient Version. 확인일 2026-05-21.
- Chronic Myeloid Leukemia Treatment (PDQ) - Health Professional Version. 확인일 2026-05-21.
- research
2010s: Treatment-free remission becomes a supervised CML research goal
Some carefully selected CML patients with deep, stable molecular responses began studying whether they could stop TKI under close monitoring.
무엇이 바뀌었나
The conversation expanded from lifelong control to supervised treatment-free remission for a subset of patients.
추정하면 안 되는 것
This is not self-stopping medicine. It requires exact response history and close molecular monitoring.
의학적 세부 내용의 출처
- chemotherapy
2017: Vyxeos approved for certain poor-prognosis AML types
A liposomal chemotherapy combination was approved for adults with therapy-related AML or AML with myelodysplasia-related changes.
무엇이 바뀌었나
AML treatment became more subtype-defined rather than one generic acute leukemia conversation.
추정하면 안 되는 것
This does not apply to every AML patient and does not replace subtype, age, fitness, mutation, and transplant discussions.
의학적 세부 내용의 출처
- cell therapy
2017: First CAR T-cell therapy approved for B-cell ALL context
A patient's own T cells could be genetically modified and returned to attack leukemia cells in a specific relapsed/refractory ALL setting.
무엇이 바뀌었나
CAR T-cell therapy became a real leukemia option in selected settings, not just a research concept.
추정하면 안 되는 것
CAR T is not for every leukemia, and it has specialized eligibility, center, toxicity, and follow-up requirements.
의학적 세부 내용의 출처
- FDA: KYMRIAH / tisagenlecleucel approval information. 확인일 2026-05-21.
- NCI: Tisagenlecleucel. 확인일 2026-05-21.
- Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) - Patient Version. 확인일 2026-05-21.